The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Shelly Selvaraj Biography and Net Worth

SVP of DexCom

Shelly R. Selvaraj serves as Senior Vice President - Information Technology of the Company. He has served as our Senior Vice President, Information Technology since October 2018, and previously served as our Vice President, Information Technology from May 2016 to October 2018. Mr. Selvaraj has a wide range of experience within global organizations in the fields of supply chain management, healthcare informatics and information technology. Prior to joining Dexcom, Mr. Selvaraj held various IT leadership roles at CareFusion, a Becton Dickinson Company, from March 2012 to May 2016, and ResMed in San Diego from April 2007 to March 2012. Earlier in his career, he worked for Motorola, Inc. and ON Semiconductor Corp. in Phoenix, Arizona. Mr. Selvaraj received a BE in Mechanical Engineering from the University of Madras and a Masters in Industrial Engineering from Arizona State University.

What is Shelly Ramasamy Selvaraj's net worth?: The estimated net worth of Shelly Ramasamy Selvaraj is at least $3.68 million as of June 15th, 2023. Mr. Selvaraj owns 50,390 shares of DexCom stock worth more than $3,678,470 as of November 14th. This net worth evaluation does not reflect any other assets that Mr. Selvaraj may own. Learn More about Shelly Ramasamy Selvaraj's net worth.
How do I contact Shelly Ramasamy Selvaraj?: The corporate mailing address for Mr. Selvaraj and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Shelly Ramasamy Selvaraj's contact information.
Has Shelly Ramasamy Selvaraj been buying or selling shares of DexCom?: Shelly Ramasamy Selvaraj has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Shelly Ramasamy Selvaraj sold 2,115 shares of the business's stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $130.00, for a transaction totalling $274,950.00. Following the completion of the sale, the senior vice president now directly owns 50,390 shares of the company's stock, valued at $6,550,700. Learn More on Shelly Ramasamy Selvaraj's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Shelly Ramasamy Selvaraj Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2023	Sell	2,115	$130.00	$274,950.00	50,390
4/20/2023	Sell	2,007	$125.00	$250,875.00	52,505
9/9/2021	Sell	2,223	$546.14	$1,214,069.22
3/11/2021	Sell	1,867	$355.86	$664,390.62
3/9/2021	Sell	152	$356.94	$54,254.88
9/9/2020	Sell	2,226	$398.30	$886,615.80
8/10/2020	Sell	400	$439.31	$175,724.00
7/10/2020	Sell	400	$439.33	$175,732.00
6/10/2020	Sell	400	$385.22	$154,088.00
5/26/2020	Sell	1,474	$408.49	$602,114.26
5/11/2020	Sell	400	$404.05	$161,620.00
4/13/2020	Sell	400	$279.88	$111,952.00
3/30/2020	Sell	1,214	$271.79	$329,953.06

Shelly Ramasamy Selvaraj Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $73.00

$71.75

$73.10

50 Day Range

MA: $69.77

$65.68

$74.85

2 Week Range

Now: $73.00

$62.34

$142.00

Volume

321,083 shs

Average Volume

3,902,181 shs

Market Capitalization

$28.51 billion

P/E Ratio

43.71

Dividend Yield

N/A

Beta

1.17

Financial Prophecy

From Porter & Company | Ad